Literature DB >> 7738957

Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire.

B M Feldman1, A Ayling-Campos, L Luy, D Stevens, E D Silverman, R M Laxer.   

Abstract

OBJECTIVE: Physical disability is perhaps the most important outcome of juvenile dermatomyositis (JDM). No functional assessment tool has been validated for inflammatory myopathies either in children or adults. We studied the measurement properties of the Childhood Health Assessment Questionnaire (CHAQ) in children with JDM.
METHODS: We studied 37 patients followed at the JDM clinic and compared the results obtained by the CHAQ to a global disease severity score and quantitative muscle strength testing measured by sphygmomanometry (construct validity). We also measured the reliability of the CHAQ and its responsiveness to clinical change.
RESULTS: For the initial measurement of each subject, the correlation between disease severity and CHAQ was high [Spearman's correlation, (rs = 0.71, p < 0.002)]. Disability as measured by the CHAQ was inversely correlated with proximal muscle strength (hip abduction rs = -0.57, p < 0.002; shoulder abduction rs = -0.51, p < 0.01) but, as expected, less so with more distal muscle strength (knee extension rs = -0.40, p = 0.05; grip strength rs = -0.079, p > 0.20). The CHAQ was reliable in subjects who showed no clinical change in muscle strength (intraclass correlation coefficient = 0.87) and responsive to treatment induced clinical change (responsiveness coefficient = 0.90).
CONCLUSION: The CHAQ can serve as a valid and sensitive tool in the evaluation of functional outcomes in JDM.

Entities:  

Mesh:

Year:  1995        PMID: 7738957

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Outcome measures and medical progress: why outcome measures are needed in childhood arthritis.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 2.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 3.  Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?

Authors:  Adam Huber; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

4.  Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry.

Authors:  Divya Challa; Cynthia S Crowson; Timothy B Niewold; Ann M Reed
Journal:  Clin Rheumatol       Date:  2017-11-23       Impact factor: 2.980

Review 5.  Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies.

Authors:  Chester V Oddis
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 6.  Outcome measures in childhood rheumatic diseases.

Authors:  L B Tucker
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

Review 7.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

Review 8.  Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.

Authors:  Adam M Huber
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 9.  The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy.

Authors:  Shabina M Sultan
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 10.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.